CA2633924C - Gastric reflux resistant dosage forms - Google Patents
Gastric reflux resistant dosage forms Download PDFInfo
- Publication number
- CA2633924C CA2633924C CA2633924A CA2633924A CA2633924C CA 2633924 C CA2633924 C CA 2633924C CA 2633924 A CA2633924 A CA 2633924A CA 2633924 A CA2633924 A CA 2633924A CA 2633924 C CA2633924 C CA 2633924C
- Authority
- CA
- Canada
- Prior art keywords
- shell
- weight
- capsule
- pectin
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002496 gastric effect Effects 0.000 title claims abstract description 77
- 239000002552 dosage form Substances 0.000 title abstract description 53
- 238000010992 reflux Methods 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 85
- 239000001814 pectin Substances 0.000 claims abstract description 43
- 229920001277 pectin Polymers 0.000 claims abstract description 40
- 229920005615 natural polymer Polymers 0.000 claims abstract description 39
- 235000010987 pectin Nutrition 0.000 claims abstract description 39
- 239000003349 gelling agent Substances 0.000 claims abstract description 22
- 229920000642 polymer Polymers 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 235000021323 fish oil Nutrition 0.000 claims abstract description 7
- 239000007903 gelatin capsule Substances 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract description 7
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 6
- 239000005017 polysaccharide Substances 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 55
- 108010010803 Gelatin Proteins 0.000 claims description 33
- 229920000159 gelatin Polymers 0.000 claims description 33
- 239000008273 gelatin Substances 0.000 claims description 33
- 235000019322 gelatine Nutrition 0.000 claims description 33
- 235000011852 gelatine desserts Nutrition 0.000 claims description 33
- 239000002775 capsule Substances 0.000 claims description 32
- 235000011187 glycerol Nutrition 0.000 claims description 26
- 241000283690 Bos taurus Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 239000004014 plasticizer Substances 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000007901 soft capsule Substances 0.000 claims description 7
- -1 galacturonic acid methyl ester Chemical class 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000003605 opacifier Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 235000019824 amidated pectin Nutrition 0.000 claims description 3
- 235000019846 buffering salt Nutrition 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- 229920000189 Arabinogalactan Polymers 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 235000019312 arabinogalactan Nutrition 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims 4
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 238000005266 casting Methods 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 13
- 239000013543 active substance Substances 0.000 abstract description 10
- 239000007787 solid Substances 0.000 abstract description 10
- 239000010647 garlic oil Substances 0.000 abstract description 4
- 239000002085 irritant Substances 0.000 abstract description 3
- 231100000021 irritant Toxicity 0.000 abstract description 3
- 206010070818 Oesophageal irritation Diseases 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 33
- 239000001110 calcium chloride Substances 0.000 description 32
- 229910001628 calcium chloride Inorganic materials 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 17
- 238000000576 coating method Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000010408 film Substances 0.000 description 5
- 239000007902 hard capsule Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007887 hard shell capsule Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000007886 soft shell capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 229930182559 Natural dye Natural products 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 229940045809 horse chestnut seed Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000000978 natural dye Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000000979 synthetic dye Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2798511A CA2798511C (en) | 2005-12-22 | 2006-12-18 | Gastric reflux resistant dosage forms |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/316,830 US20070148248A1 (en) | 2005-12-22 | 2005-12-22 | Gastric reflux resistant dosage forms |
| US11/316,830 | 2005-12-22 | ||
| PCT/US2006/048029 WO2007075475A2 (en) | 2005-12-22 | 2006-12-18 | Gastric reflux resistant dosage forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2798511A Division CA2798511C (en) | 2005-12-22 | 2006-12-18 | Gastric reflux resistant dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2633924A1 CA2633924A1 (en) | 2007-07-05 |
| CA2633924C true CA2633924C (en) | 2013-11-19 |
Family
ID=38007176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2633924A Active CA2633924C (en) | 2005-12-22 | 2006-12-18 | Gastric reflux resistant dosage forms |
| CA2798511A Active CA2798511C (en) | 2005-12-22 | 2006-12-18 | Gastric reflux resistant dosage forms |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2798511A Active CA2798511C (en) | 2005-12-22 | 2006-12-18 | Gastric reflux resistant dosage forms |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US20070148248A1 (enExample) |
| EP (3) | EP2716283B1 (enExample) |
| JP (2) | JP5627854B2 (enExample) |
| CA (2) | CA2633924C (enExample) |
| ES (3) | ES2538803T3 (enExample) |
| WO (1) | WO2007075475A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2498207C (en) * | 2002-09-11 | 2012-03-13 | Elan Pharma International Ltd. | Gel-stabilized nanoparticulate active agent compositions |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| KR101245604B1 (ko) | 2007-11-13 | 2013-03-21 | 메리테이지 파마, 인크. | 코르티코스테로이드 조성물 |
| US20090143343A1 (en) | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| WO2013093630A2 (en) | 2011-12-22 | 2013-06-27 | Pronova Biopharma Norge As | Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof |
| WO2013155430A1 (en) * | 2012-04-13 | 2013-10-17 | Banner Pharmacaps, Inc. | Soft elastic capsules containing tablets and liquid or semisolid fills and methods for their manufacture |
| JP2014172850A (ja) | 2013-03-07 | 2014-09-22 | Capsugel Belgium Nv | ハードカプセル製剤 |
| AU2014240170B2 (en) * | 2013-03-15 | 2018-05-17 | Patheon Softgels Inc. | Silk-based capsules |
| CA2911643C (en) | 2013-05-23 | 2018-01-16 | Barlean's Organic Oils, Llc | Rotary die system |
| MX2016004487A (es) | 2013-10-30 | 2016-11-10 | Banner Life Sciences Llc | Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados. |
| US20150366814A1 (en) * | 2014-06-23 | 2015-12-24 | Banner Life Sciences Llc | All-natural enteric soft capsules comprising active ingredients |
| US9895333B2 (en) | 2014-06-26 | 2018-02-20 | Patheon Softgels Inc. | Enhanced bioavailability of polyunsaturated fatty acids |
| HUE053962T2 (hu) | 2014-09-11 | 2021-08-30 | Gelita Ag | Zselatin/pektin részecskék |
| WO2016056230A1 (ja) * | 2014-10-06 | 2016-04-14 | 富士カプセル株式会社 | 腸溶性ソフトカプセルの製造方法 |
| SG11201702752RA (en) | 2014-10-06 | 2017-06-29 | Fuji Capsule Co Ltd | Method of Manufacturing Enteric Seamless Soft Capsule |
| KR20170076675A (ko) | 2014-10-31 | 2017-07-04 | 발린스 오르개닉 오일스, 엘.엘.씨. | 소프트젤을 제조하기 위한 방법 및 장치 |
| ITUB20156821A1 (it) * | 2015-12-09 | 2017-06-09 | Altergon Sa | CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE |
| CN105534945B (zh) * | 2015-12-29 | 2020-12-25 | 仙乐健康科技股份有限公司 | 一种植物型肠溶软胶囊 |
| US20240408025A1 (en) * | 2021-09-13 | 2024-12-12 | Nutrition & Biosciences Usa 1, Llc | A film-forming composition comprising pectin |
| DE102022104553A1 (de) * | 2022-02-25 | 2023-08-31 | Gelita Ag | Magensaftresistente Kapsel und deren Verwendung |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58172313A (ja) | 1982-04-01 | 1983-10-11 | Morishita Jintan Kk | 腸溶性軟カプセル |
| JPS58194810A (ja) * | 1982-05-07 | 1983-11-12 | Morishita Jintan Kk | コ−テイング軟ミニカプセル |
| US4719112A (en) * | 1982-10-29 | 1988-01-12 | Warner-Lambert Company | Foam capsules |
| US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4816259A (en) * | 1987-02-12 | 1989-03-28 | Chase Chemical Company, L.P. | Process for coating gelatin capsules |
| US6482516B1 (en) * | 1993-07-20 | 2002-11-19 | Banner Pharmacaps, Inc. | Enrobed tablet |
| US5146730A (en) * | 1989-09-20 | 1992-09-15 | Banner Gelatin Products Corp. | Film-enrobed unitary-core medicament and the like |
| US5264223A (en) * | 1990-03-29 | 1993-11-23 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| JPH0427352A (ja) * | 1990-05-22 | 1992-01-30 | Fuji Capsule Kk | 健康食品用腸溶性軟カプセル |
| DE4018247A1 (de) * | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen |
| US5164184A (en) * | 1990-10-11 | 1992-11-17 | Kim Young S | Process for the preparation of pharmaceutical liquid composition containing Bezoar bovis |
| JPH05245366A (ja) * | 1992-03-04 | 1993-09-24 | Morishita Jintan Kk | 内側面が非水溶化された皮膜を有するシームレスカプセルとその製造方法 |
| MX9301823A (es) * | 1992-03-30 | 1994-01-31 | Alza Corp | Composicion para el suministro de liberacion controlado de un agente biologicamente activo. |
| NZ244796A (en) * | 1992-08-18 | 1995-05-26 | Scherer Corp R P | Capsule shell of soft gelatin contains a medicament and has a removable tab |
| US5330759A (en) * | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
| US5431917A (en) * | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| US5726274A (en) * | 1994-12-21 | 1998-03-10 | Basf Corporation | Polyurethane polymer or oligomer having carbamate groups, method for its preparation, and coating composition |
| US20010003647A1 (en) | 1995-06-07 | 2001-06-14 | Ji Sun | Coreatant-including electrochemiluminescent compounds, methods, systems and kits utilizing same |
| KR100219918B1 (ko) | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
| WO1999033924A1 (en) * | 1997-12-26 | 1999-07-08 | Warner-Lambert Company | Gelatine compositions |
| MXPA01003197A (es) * | 1998-09-28 | 2004-04-21 | Warner Lambert Co | Suministro enterico y colonico utilizando capsulas de chpm. |
| PT1117736E (pt) | 1998-09-30 | 2004-10-29 | Warner Lambert Co | Composicoes de pelicula de amido modificado |
| EP1072633A1 (en) | 1999-07-22 | 2001-01-31 | Warner-Lambert Company | Pullulan film compositions |
| US6346231B1 (en) * | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
| KR100379674B1 (ko) * | 2000-03-06 | 2003-04-10 | 주식회사 서흥캅셀 | 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법 |
| US6620571B2 (en) * | 2000-03-17 | 2003-09-16 | Eastman Kodak Company | Method for producing microcapsules having improved wall characteristics |
| CN1141974C (zh) * | 2000-06-07 | 2004-03-17 | 张昊 | 结肠定位释放的口服生物制剂 |
| EP1184033A1 (en) * | 2000-09-01 | 2002-03-06 | Warner-Lambert Company | Pectin film compositions |
| EP1186626A1 (en) * | 2000-09-05 | 2002-03-13 | Warner-Lambert Company | Composition for soluble films with a new hydrolyzed polysaccharide |
| US6683019B2 (en) * | 2001-06-13 | 2004-01-27 | Abb Lummus Global Inc. | Catalyst for the metathesis of olefin(s) |
| JP4184278B2 (ja) | 2001-11-22 | 2008-11-19 | 森下仁丹株式会社 | 非ゼラチン系カプセル皮膜組成物及びそれを用いたカプセル |
| NO20021592D0 (no) * | 2002-04-04 | 2002-04-04 | Fmc Biopolymer As | Polysakkaridkapsler og fremgangsmåte ved fremstilling derav |
| US20040010069A1 (en) | 2002-06-27 | 2004-01-15 | Uniroyal Chemical Company, Inc. | Rubber compositions and methods for improving the mooney scorch value and cure rate |
| DK1545475T3 (da) * | 2002-10-01 | 2014-07-28 | Banner Pharmacaps Inc | Enterisk sammensætning til fremstillingen af blød kapselvæg |
| ATE340566T1 (de) | 2002-12-05 | 2006-10-15 | Symrise Gmbh & Co Kg | Nahtlose gefüllte kapseln |
| US7396874B2 (en) * | 2002-12-06 | 2008-07-08 | Hercules Incorporated | Cationic or amphoteric copolymers prepared in an inverse emulsion matrix and their use in preparing cellulosic fiber compositions |
| CA2510465A1 (en) * | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| KR100505530B1 (ko) * | 2003-09-29 | 2005-08-03 | 주식회사 서흥캅셀 | 어류 젤라틴을 이용한 하드 캅셀 및 그의 제조방법 |
| JP4027352B2 (ja) | 2004-09-17 | 2007-12-26 | アンリツ株式会社 | 光ファイバプローブ装置 |
| DE102007039772A1 (de) | 2007-08-22 | 2009-02-26 | Cavis Microcaps Gmbh | Mikrokapsel und Verfahren zu deren Herstellung |
| JP5245366B2 (ja) | 2007-11-14 | 2013-07-24 | 王子ホールディングス株式会社 | 偏光板およびその製造方法 |
-
2005
- 2005-12-22 US US11/316,830 patent/US20070148248A1/en not_active Abandoned
-
2006
- 2006-12-18 CA CA2633924A patent/CA2633924C/en active Active
- 2006-12-18 EP EP14150121.3A patent/EP2716283B1/en active Active
- 2006-12-18 WO PCT/US2006/048029 patent/WO2007075475A2/en not_active Ceased
- 2006-12-18 EP EP15163491.2A patent/EP2923696B1/en active Active
- 2006-12-18 ES ES14150121.3T patent/ES2538803T3/es active Active
- 2006-12-18 ES ES06845613.6T patent/ES2549858T3/es active Active
- 2006-12-18 EP EP06845613.6A patent/EP1973533B1/en active Active
- 2006-12-18 ES ES15163491.2T patent/ES2687807T3/es active Active
- 2006-12-18 CA CA2798511A patent/CA2798511C/en active Active
- 2006-12-18 JP JP2008547361A patent/JP5627854B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-03 US US12/716,593 patent/US9693966B2/en active Active
-
2013
- 2013-06-06 JP JP2013119371A patent/JP2013209416A/ja active Pending
- 2013-11-12 US US14/078,156 patent/US8962005B2/en not_active Expired - Lifetime
-
2014
- 2014-10-06 US US14/507,327 patent/US9192582B2/en not_active Expired - Lifetime
-
2017
- 2017-05-23 US US15/602,700 patent/US10182990B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2549858T3 (es) | 2015-11-02 |
| ES2687807T3 (es) | 2018-10-29 |
| EP1973533A2 (en) | 2008-10-01 |
| US8962005B2 (en) | 2015-02-24 |
| CA2633924A1 (en) | 2007-07-05 |
| EP2716283B1 (en) | 2015-04-15 |
| JP2013209416A (ja) | 2013-10-10 |
| US20170281555A1 (en) | 2017-10-05 |
| US20150024044A1 (en) | 2015-01-22 |
| CA2798511C (en) | 2015-04-14 |
| US20070148248A1 (en) | 2007-06-28 |
| EP1973533B1 (en) | 2015-07-29 |
| EP2923696B1 (en) | 2018-07-11 |
| ES2538803T3 (es) | 2015-06-24 |
| EP2716283A1 (en) | 2014-04-09 |
| CA2798511A1 (en) | 2007-07-05 |
| JP5627854B2 (ja) | 2014-11-19 |
| EP2923696A1 (en) | 2015-09-30 |
| JP2009521269A (ja) | 2009-06-04 |
| WO2007075475A2 (en) | 2007-07-05 |
| WO2007075475A3 (en) | 2007-12-13 |
| US20140072625A1 (en) | 2014-03-13 |
| US9693966B2 (en) | 2017-07-04 |
| US20100158958A1 (en) | 2010-06-24 |
| US9192582B2 (en) | 2015-11-24 |
| US10182990B2 (en) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10182990B2 (en) | Gastric reflux resistant dosage forms | |
| Gullapalli et al. | Gelatin and non-gelatin capsule dosage forms | |
| CA2500663C (en) | Enteric composition for the manufacture of soft capsule wall | |
| JP6317425B2 (ja) | シルク系カプセル剤 | |
| JP2000514406A (ja) | アルギン酸から成る経口投与製剤用腸溶性被膜 | |
| US20070082046A1 (en) | Enteric valproic acid | |
| CN107921142A (zh) | 肠溶胶囊 | |
| US20060088590A1 (en) | Non-blooming gelatin and non-gelatin formulations | |
| JP7719609B2 (ja) | 腸溶性硬質カプセル | |
| JPWO2005011402A1 (ja) | 咀嚼性カプセル及びその製造方法 | |
| US20160106682A1 (en) | Enteric Soft Capsules | |
| RU2822392C2 (ru) | Капсулы задержанного высвобождения из мягкого желатина | |
| JPH0710746A (ja) | 服用時の付着性を改良した硬カプセル剤 | |
| JP2019099473A (ja) | ソフトカプセル | |
| US20170281554A1 (en) | System for upper intestinal delivery of active ingredients | |
| CN107441500A (zh) | 结肠靶向给药口服制剂成膜组合物及制备方法、应用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |